T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies
Pharmaceutical Technology
JANUARY 10, 2023
billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.
52 
Let's personalize your content